TEVA PHARMACEUTICAL INDUSTRIES LTD 8K

Teva priced approximately $4.9 billion equivalent of new senior notes to refinance and redeem multiple existing higher-coupon and sustainability-linked notes and for general corporate purposes.

Teva Pharmaceutical Industries Ltd. announced that it has successfully priced approximately $4.9 billion equivalent of new senior notes across multiple EUR- and USD-denominated tranches maturing between 2032 and 2037, to be issued by its Netherlands finance subsidiaries and guaranteed by Teva. Settlement is expected around September 16, 2026, subject to customary conditions, and the proceeds, together with cash on hand, will be used primarily to fund conditional redemptions of various higher-coupon and sustainability-linked senior notes maturing between 2027 and 2031 (and 2030), to pay related fees and expenses, and for general corporate purposes including future debt repayment. Teva has already issued several notices of conditional redemption and plans an additional notice to redeem all 8.125% USD Sustainability-Linked Senior Notes due 2031 and to slightly reduce the amount of 4.375% Sustainability-Linked Senior Notes due 2030 being redeemed, thereby extending and optimizing its debt maturity profile and interest cost structure under an existing automatic shelf registration statement on Form S-3.

Filing Facts

CIK

818686

Ticker

TEVA

Form

8K

Source Type

fda

Accession

0001193125-26-389264

Alert Tier

7